

**Complete if Known**

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Application Number	
Filing Date	04/14/2004
First Named Inventor	M. Zouhair Atassi
Art Unit	
Examiner Name	
Attorney Docket Number	MSC-21947-1-CU

[illegible][illegible]Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet 2 of 3	Application Number	
	Filing Date	04/14/2004
	First Named Inventor	M. Zouhair Atassi
	Art Unit	
	Examiner Name	
	Attorney Docket Number	MSC-21947-1-CU

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MORRISON et al; Electrophoretic Separation of Kidney and Pituitary Cells on STS-8; Adv. Space Res.; Vol. 4, No. 5, pp 67-76, 1984, Great Britian	
		SIBLEY et al; Enhancement Effect of Storage Buffer on Regeneration of Immunosorbent Surfaces; Benchmarks	
		VERSTRAETE et al; Pharmacology of Thrombolytic Drugs; JACC Vol. 8, No. 6, December 1986, pp33B-40B, Leuven, Belgium	
		BARLOW et al; Secretion of plasminogen actiator by the human macrophage-like cell line, GCT...; British Journal of Haematology, 1982, 52, pp645-655	
		SWANK et al; Parallel line analysis: multifunctional software for the biomedical sciences; Computer Methods and Programs in Biomedicine, 33 (1990) pp95-105	
		BARLOW et al; Identification of the Plasminogen Activator(s) produced by the Transformed Liver Cell Line, SK-HEP-1; Thrombosis Research 32; 1983, pp29-34	
		SCHMITT et al; Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in ...; Blood Coagulation and Fibrinolysis, 1990, pp695-702	
		HASUI et al; Comparative Study of Plasminogen Activators in Cancers and Normal Mucosae of Human Unirary Bladder; Cancer Research 49, 1067-1070, 2/15/1989	
		GAYLIS et al; Plasminogen Activators in Human Prostate Cancer Cell Lines and Tumors: Correlation with the Aggressive Phenotype; The Journal of Urology; Vol 142, 1989, pp193-198	
		VERSTRAETE et al; Thrombolytic Therapy in the Eighties; Journal of the American Society of Hematology; Vol. 67, No. 6 June 1986, pp1539-1541	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number

Filing Date

4/14/2004

First Named Inventor

Z. Mouhair Atassi

Art Unit

Examiner Name

Sheet

3

of

3

Attorney Docket Number

MSC-21947-1-CU

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SCHMITZ et al; Production of Monoclonal Antibodies with Pre-Selected Submolecular Binding Specificities to Protein...; Molecular Immunology; Vol. 19, No. 12, pp. 1699-1701	
		ACTON et al; Eukaryotic Cell Cultures Basics and Applications; Plenum Press; pp 241-267	
		ERICKSON; Sensible Biology; Scientific American, July 1992, pp 110-111	
		MORRISON et al; Experiment Sequence Test Report for Biorack Experiment 01.2-I, "ANTIGEN"; International Microgravity Laboratory Mission No. 2 (IML-2)	
		MORRISON et al; Preliminary Science Report No. 2; IML-2 STS-65; 4/21/1995	
		ATASSI; Analysis of Electrophoresis Samples and Antibody Applications; Final Progress Report NAS9-18065; 10/24/1995	
		ATASSI; Analysis of uPA in Supernatants from Kidney Cell Culture Flight Samples; Contract No. NAS9-18065	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.